Sunday Sep 7, 2008 (foodconsumer.org)
-- The FDA on Sep. 5, 2008 announced that it will publish quarterly a
list of drugs that are being evaluated by the agency for its
potential risks that have not been known earlier.
The listed drugs will be identified
based on a review of reports in the agency's Adverse Event Reporting
System (ARS).
The FDA move was authorized by the Food
and Drug Administration Amendments Act, a law that got approved on
Sept. 27, 2007 as cited below.
Title IX, Section 921 of the Food and
Drug Administration Amendments Act 2007 (FDAAA) (121 Stat. 962)
amends the Federal Food, Drug and Cosmetic Act (FDCA) to add a new
subsection (k)(5) to section 505 (21 U.S.C. 355).
This section in FDAAA, among other
things, directs FDA to "conduct regular, bi-weekly screening of
the Adverse Event Reporting System [AERS] database and post a
quarterly report on the Adverse Event Reporting System Web site of
any new safety information or potential signal of a serious risk
identified by Adverse Event Reporting System within the last
quarter." When a potential signal of a serious risk is
identified from AERS data, it will be posted in the required report
in the quarter in which it is first identified. A potential signal of
a serious risk may in some cases constitute new safety information as
defined in FDAAA (newly created section 505-1(b)(3) of the FDCA)
which includes, among other things, information derived from adverse
event reports about a serious risk associated with use of a drug that
FDA has become aware of since the drug was approved or, for drugs
that have REMS, since the REMS was required or last assessed. FDA
will post each potential signal of a serious risk in the quarter in
which it is first identified. If additional new safety information is
developed concerning a potential signal that has already been posted,
it will be addressed by FDA in new safety communications, but will
not appear again as a new quarterly posting.
The law requires that FDA inform the
public each quarter of the new safety information or potential
serious risks based on the agency's review of the reports in AERS.
The FDA says in its announcement though
that getting listed on the quarterly report does not mean the drugs
definitely cause the listed risks and a causal relationship has yet
to be proved.
Patients should continue taking any
drug on the list if their doctors prescribe, said Janet Woodcock,
M.D., director of FDA's Center for Drug Evaluation and Research.
The first quarterly report, published
on Sep. 5, lists 20 drugs along with their potential safety issue.
Future reports will only list NEW drugs that have not been listed in
previous reports.
Below are the first quarterly report cited from the FDA website.
Potential Signals of Serious Risks/New Safety Information
Identified by the Adverse Event Reporting System (AERS)
January - March 2008
The table below lists the names of products and potential signals
of serious risks/new safety information that were identified for
these products during the period January - March 2008 in the AERS
database. The appearance of a drug on this list does not mean that
FDA has concluded that the drug has the listed risk. It means that
FDA has identified a
potential safety issue, but does not
mean that FDA has identified a causal relationship between the drug
and the listed risk. If after further evaluation the FDA determines
that the drug is associated with the risk, it may take a variety of
actions including requiring changes to the labeling of the drug,
requiring development of a Risk Evaluation and Mitigation Strategy
(REMS), or gathering additional data to better characterize the risk.
FDA wants to emphasize that the listing of a drug and a potential
safety issue on this Web site does not mean that FDA is suggesting
prescribers should not prescribe the drug or that patients taking the
drug should stop taking the medication. Patients who have questions
about their use of the identified drug should contact their health
care provider. FDA will complete its evaluation of each potential
signal/new safety information and issue additional public
communications as appropriate.
Potential Signals of Serious Risks/New Safety
Information Identified by the Adverse Event Reporting System (AERS)
January - March 2008
|
Product Name: Active Ingredient (Trade)
or Product
Class
|
Potential Signal of Serious Risk/New Safety
Information
|
|
Arginine Hydrochloride Injection (R-Gene 10)
|
Pediatric overdose due to labeling / packaging confusion
|
|
Desflurane (Suprane)
|
Cardiac arrest
|
|
Duloxetine (Cymbalta)
|
Urinary retention
|
|
Etravirine (Intelence)
|
Hemarthrosis
|
|
Fluorouracil Cream (Carac) and Ketoconazole Cream (Kuric)
|
Adverse events due to name confusion
|
|
Heparin
|
Anaphylactic-type reactions
|
|
Icodextrin (Extraneal)
|
Hypoglycemia
|
|
Insulin U-500 (Humulin R)
|
Dosing confusion
|
|
Ivermectin (Stromectol) and Warfarin
|
Drug interaction
|
|
Lapatinib (Tykerb)
|
Hepatotoxicity
|
|
Lenalidomide (Revlimid)
|
Stevens Johnson Syndrome
|
|
Natalizumab (Tysabri)
|
Skin melanomas
|
|
Nitroglycerin (Nitrostat)
|
Overdose due to labeling confusion
|
|
Octreotide Acetate Depot (Sandostatin LAR)
|
Ileus
|
|
Oxycodone Hydrochloride Controlled-Release (Oxycontin)
|
Drug misuse, abuse and overdose
|
|
Perflutren Lipid Microsphere (Definity)
|
Cardiopulmonary reactions
|
|
Phenytoin Injection (Dilantin)
|
Purple Glove Syndrome
|
|
Quetiapine (Seroquel)
|
Overdose due to sample pack labeling confusion
|
|
Telbivudine (Tyzeka)
|
Peripheral neuropathy
|
|
Tumor Necrosis Factor (TNF) Blockers
|
Cancers in children and young adults
|
Date created: September 5, 2008